Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Is anticoagulation with aspirin or apixaban effective for improving outcomes in clinically stable adults with symptomatic COVID-19?
Bottom line
This study found no benefit to either aspirin or apixaban for reducing adverse events among initially stable adults with symptomatic COVID-19. No reported major bleeding events occurred during the clinical trial or during follow-up. The study was terminated early because of lower-than-anticipated event rates. 1b
Reference
Study design: Randomized controlled trial (double-blinded)
Funding: Industry + foundation
Setting: Outpatient (any)
Synopsis
The balance of benefit versus harm of antithrombotic therapy for clinically stable outpatients with symptomatic COVID-19 remains uncertain. These investigators identified outpatient adults, aged 40 years to 80 years, with newly diagnosed symptomatic SARS-CoV-2 infection by positive PCR or antigen test. Study patients (N = 657) randomly received (concealed allocation assignment) aspirin (81 mg once daily) plus placebo, apixaban 2.5 mg twice daily, apixaban 5.0 mg twice daily, or placebo twice daily. The individuals who assessed outcomes remained masked to treatment group assignments. The trial was terminated early because of lower-than-anticipated event rates, resulting in a total of 558 patients who initiated trial treatment. Complete follow-up occurred for 99.6% of these 558 patients at 45 days or time of trial termination. Using intention-to-treat analysis of all randomized patients, no significant group differences occurred in the risk of the primary composite end point of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, or hospitalization. Overall excess bleeding events were increased in both the aspirin and apixaban groups compared with the placebo-only group, but no major bleeding events occurred in any group.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC
Comments
anticoagulation rx for asa or eliquis does not improve outco
no routine anticoagulant use for asymptomatic covid pts